{"disease":{"id":"hepatitis-viral-human","name":"hepatitis viral human"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00342186","title":"Genes Involved in Resistance or Susceptibility to Hepatitis B Virus","phase":"","overall_status":"COMPLETED","enrollment_count":2303,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00913757","title":"A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05492565","title":"Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Hospitales Universitarios Virgen del Rocío","has_results":false},{"nct_id":"NCT02613403","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":94,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03410953","title":"Vaccination Adjuved Against Hepatitis B in SNS Workers Typed as no Responders to Conventional Vaccines","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León","has_results":true},{"nct_id":"NCT01532973","title":"Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}